{"id":1646,"date":"2023-06-25T17:29:04","date_gmt":"2023-06-25T17:29:04","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/aripiprazole\/"},"modified":"2023-06-25T19:59:41","modified_gmt":"2023-06-25T19:59:41","slug":"aripiprazole","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/aripiprazole\/","title":{"rendered":"Aripiprazole"},"content":{"rendered":"

<\/p>\n

Aripiprazole<\/h1>\n

CLINICAL USE<\/h3>\n

Atypical antipsychotic for the treatment of
\nschizophrenia<\/p>\n

DOSE IN NORMAL RENAL FUNCTION<\/h3>\n

10\u201330 mg daily<\/p>\n

PHARMACOKINETICS<\/h3>\n
  • Molecular weight                           :
    \n448.4<\/li>\n
  • %Protein binding                           :
    \n>99<\/li>\n
  • %Excreted unchanged in urine     :
    \n<1<\/li>\n
  • Volume of distribution (L\/kg)       :
    \n4.9<\/li>\n
  • half-life \u2013 normal\/ESRD (hrs)      :
    \n75 (146 in poor
    \nmetabolisers)\/
    \nUnchanged<\/p>\n

    DOSE IN RENAL IMPAIRMENT<\/h3>\n

    GFR (mL\/MIN)<\/h4>\n<\/li>\n
  • 20 to 50     : Dose as in normal renal function<\/li>\n
  • 10 to 20     : Dose as in normal renal function<\/li>\n
  • <10           :
    \nDose as in normal renal function<\/p>\n

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES<\/h3>\n<\/li>\n
  • CAPD                :
    \nNot dialysed. Dose as in normal renal function<\/li>\n
  • HD                     :
    \nNot dialysed. Dose as in normal renal function<\/li>\n
  • HDF\/high flux   :
    \nUnlikely to be dialysed. Dose as in
    \nnormal renal function<\/li>\n
  • CAV\/VVHD      :
    \nNot dialysed. Dose as in normal renal function<\/p>\n

    IMPORTANT DRUG INTERACTIONS<\/h3>\n

    Potentially hazardous interactions with other drugs<\/li>\n

  • Anaesthetics: enhanced hypotensive effect<\/li>\n
  • Analgesics: increased risk of convulsionswith tramadol; enhanced hypotensive and
    \nsedative effects with opioids
    \nAntihypertensives: may enhance<\/p>\n

    antihypertensive effect<\/li>\n

  • Alcohol and other CNS drugs: increasedsedation and other related side effects<\/li>\n
  • Anti-arrhythmics: increased risk ofventricular arrhythmias with anti-
    \narrhythmics that prolong the QT interval<\/li>\n
  • Antibacterials: concentration possiblyreduced by rifabutin and rifampicin \u2013
    \nincrease dose of aripiprazole<\/li>\n
  • Antidepressants: fluoxetine and paroxetinepossibly inhibit metabolism \u2013 reduce dose
    \nof aripiprazole; concentration possibly
    \nreduced by St John\u2019s wort \u2013 increase
    \naripiprazole dose; increased concentration
    \nof tricyclics<\/li>\n
  • Anti-epileptics: antagonises anticonvulsanteffect; concentration reduced by
    \ncarbamazepine and possibly reduced by
    \nphenytoin, phenobarbital and primidone \u2013
    \nincrease dose of aripiprazole
    \nAntifungals: metabolism inhibited by<\/p>\n

    ketoconazole and possibly by itraconazole
    \nreduce dose of aripiprazole<\/li>\n

  • Antimalarials: avoid concomitant use withartemether\/lumefantrine<\/li>\n
  • Antivirals: metabolism possibly inhibitedby amprenavir, atazanavir, indinavir,
    \nlopinavir, nelfinavir, ritonavir and
    \nsaquinavir \u2013 reduce dose of aripiprazole;
    \nconcentration possibly reduced by
    \nefavirenz and nevirapine \u2013 increase dose
    \nof aripiprazole<\/li>\n
  • Anxiolytics and hypnotics: increasedsedative effects
    \nS<\/li>\n
  • ibutramine: increased risk of CNStoxicity \u2013 avoid concomitant use
    \n

    ADMINISTRATION<\/h3>\n

    Reconstition<\/h4>\n

    \u2013<\/p>\n

    Route<\/h4>\n

    Oral<\/p>\n

    Rate of Administration<\/h4>\n

    \u2013<\/p>\n

    Comments<\/h4>\n

    \u2013<\/p>\n

    OTHER INFORMATION<\/h4>\n

    Hepatic metabolism and elimination<\/p>\n

    Can cause QT prolongation<\/li>\n","protected":false},"excerpt":{"rendered":"

    Aripiprazole CLINICAL USE Atypical antipsychotic for the treatment of schizophrenia<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-1646","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/1646","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=1646"}],"version-history":[{"count":1,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/1646\/revisions"}],"predecessor-version":[{"id":2948,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/1646\/revisions\/2948"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=1646"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=1646"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=1646"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}